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Abstract: 
Background 
Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much smaller 
burden of treatment than interferon-based regimes, require less monitoring and are very 
effective. New pathways are required to increase access to treatment amongst people 
prescribed opioid substitution therapy (OST). 
Method 
An exploratory cluster randomised controlled trial with mixed methods evaluation was 
undertaken to compare the uptake of dried blood spot testing (DBST) and treatment of 
people with genotype 1 HCV infection in a conventional service pathway versus a 
pharmacist-led pathway in a population receiving OST. 
Results 
Pharmacies randomised to the conventional pathway obtained 58 DBST from 244 patients 
(24%):15 new reactive tests and 33 new negative tests were identified. Within the 
pharmacist-led pathway, 94 DBST were obtained from 262 patients (36%): 26 new reactive 
tests and 54 new negative tests were identified.  Participants in the pharmacist-led pathway 
were more likely to take a DBST (p=0.003).  Of participants referred for treatment through 
the conventional pathway, 4 patients from 15 with new reactive tests (27%) attended clinic 
for assessment. In the pharmacist-led treatment pathway, 20 patients from 26 with new 
reactive tests (77%) attended for assessment blood tests.  Participants in the pharmacist-led 
pathway were more likely to proceed through the assessment for treatment (p=0.002).  One 
participant completed treatment through the conventional pathway and three patients 
completed treatment through the pharmacist-led pathway.  The process evaluation identified 
key themes important to service user completers and staff participants. 
Conclusion  
The study provides evidence that testing and treatment for HCV in a pharmacist led-pathway 
is a feasible treatment pathway for people who receive supervised OST consumption 
through community pharmacies.  This feasibility trial therefore provides sufficient 
confirmation to justify proceeding to a full trial  
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Introduction 
Hepatitis C (HCV) is a blood-borne viral infection (BBV) causing liver disease.  Around 0.8% 
of the Scottish population are chronically infected with HCV (Scottish Intercollegiate 
Guidelines Network, 2013).  A recent Public Health England report highlighted that less than 
3% of those known to be infected with HCV are being treated and less than half of those 
infected are known (Public Health England, 2016).  The largest single infected group are 
those on opioid substitution therapy (OST) (Arain, 2014). Research suggests around 40% of 
people receiving OST have HCV (Aspinall, 2015; Edlin 2005) 
The world-wide burden of HCV infection has been estimated as 71.1 million infections 
(62.5—79.4), with the largest group being genotype1 (Polaris Observatory HCV 
Collaborators 2017).  The increased morbidity, mortality and economic impact of the 
infection are of concern to both industrialised and developing countries (Lavanchy, 2009). 
The paradigm shift resulting from the introduction of Directly Acting Antiviral drugs (DAAs) 
has changed the narrative around HCV, with a realisation that HCV could be eliminated in 
people who inject drugs (Lima, 2015).  There is optimism that the use of DAAs offers a high 
chance of clearance of HCV infection from the population (Grebely, 2014).  Treating all 
patient groups with HCV would yield substantial benefits (van Nuys, 2014) but there are 
concerns that the infrastructure and treatment capacity to deliver the required health 
outcomes are not generally available or of insufficient scale (Leask, 2016). 
Treatment uptake for HCV amongst people who inject drugs is currently low (Weissing, 
2014) and prospective patients may have a number of barriers to overcome in order to 
access care (Fernandez-Montero, 2014).  There are identified deficiencies in the extent of 
screening and diagnosis of at-risk populations, as well as improvements required in access 
to treatment initiation and clinical monitoring (Artenie, 2015): People who inject drugs may 
find it difficult to consistently attend medical clinics (Papatheodoridis, 2014).  However, the 
delivery of HCV testing and treatment through community-based care pathways has been 
shown to be feasible (Wade, 2016) and Dried Blood Spot Testing (DBST) has been 
demonstrated to increase the uptake of testing from high-risk populations (Coats and Dillon, 
2015). 
Creating the complex interventions necessary to eliminate HCV requires that well-designed 
cross-disciplinary programmes are put in place (Suther and Harries, 2015) using different 
strategies to increase screening, testing and diagnosis (Brouard et al, 2015).  The potential 
of community pharmacy practices to make a greater contribution to the health of their local 
populations has been recognised for some time (Anderson et al, 2009).  Pharmacists have 
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long had a major role in delivering OST to this group of patients with a high prevalence of 
HCV (Anderson, 2007) and pharmacist involvement in delivering HCV treatment through 
multi-disciplinary clinics has been described for some time (Kolor 2005, Arora 2011) 
The Tayside region of Scotland has sequentially developed integrated HCV treatment 
services over the last two decades, moving from standard secondary care-based hospital 
outpatients, onto nurse-supported treatment services, then to a HCV managed care network 
(MCN) including a widespread dry blood spot testing programme in drug services and 
development in our outreach services across the region. This most recent development 
includes providing treatment within drug services and prisons (Tait 2016).  The network aims 
for wide involvement in BBV testing and follow-up, with healthcare professionals such as 
drug workers, GPs, prison nurses and social workers taking the opportunity to discuss 
referral and treatment with patients. 
A cluster randomised feasibility trial was therefore designed to optimise the research design 
and consider whether a pharmacist-led testing and treatment pathway could be both 
effective and successful, before being more widely implemented (Bowen et al 2009).  The 
study was designed with a mixed methods approach to evaluate: whether people who 
receive OST for pharmacies could be recruited to the study; whether pharmacies could 
successfully complete all elements of the testing and treatment pathway; which elements of 
the pathway work well and which elements are less successful; to make an estimate of the 
effect size in terms of how many participants complete each stage of the pathway (Eldridge 
et al 2016; Arain et al 2010). 
In preparing to undertake this study, work was undertaken using a co-production approach in 
partnership with OST patients (Radley et al, 2016) and has developed the intervention 
through using the views of patients and staff to identify barriers and facilitators to effective 
care (Radley et al, 2017).  The DOT-C study utilises the existing pharmacy environment and 
therapeutic relationships to smooth the pathway into HCV therapy and co-administer OST 
with anti-HCV therapy under the supervision of the pharmacist.  The conventional care 
pathway requires referral and attendance of the patient at another site and treatment 
according to the established standard of care. This feasibility study therefore aims to 
address questions about increasing testing and uptake of treatment, through a simplified 
community pharmacist-led care pathway for patients with genotype 1 HCV and to 
incorporate these colleagues into the work of the MCN. 
Methods 
Trial design: 
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An exploratory cluster randomised trial of directly observed anti HCV therapy versus 
conventional care in HCV positive patients attending a pharmacist delivered OST program.  
 
Study protocol: Ethics approval was received for this study (15/ES/0086) from East of 
Scotland REC2 on 2 July 2015. Caldicott Guardian approval was given on 25 July 2015  
Participants: 
Approximately 2,200 patients are prescribed OST within the Tayside region of North East 
Scotland. Around 85% of these patients receive daily supervision of their OST consumption 
through the 92 community pharmacies. At least 40% of these patients will be infected with 
HCV, 40% of infections are Genotype 1 virus (Hutchinson et al, 2006).  
Trial inclusion criteria  
Pharmacies were eligible to participate in the study if they could offer DBST for HCV or be 
trained to do so.  Pharmacies required around 30 patients to ensure adequate recruitment. 
Patients were eligible to be consented to the study if they were prescribed OST with 
supervised administration by a pharmacist and had a reactive DBST. Only genotype 1 
patients were included.  Genotype 3 patients were excluded because of the requirement to 
provide interferon-based regimes at the time of the study. 
Randomisation: 
Eight pharmacies were randomised into two groups: conventional care and pharmacist-led 
care.  Randomisation was carried out using http://www.randomization.com.  The subjects 
were randomized into one block using the seed 12576 along with the number of subjects per 
block/number of blocks and (case-sensitive) treatment labels.  The pharmacy provided the 
level of randomisation, so patient allocation was dependent on the pharmacy attended. 
Interventions: 
All pharmacy staff involved with the study received training on good clinical practice, study 
procedures and documentation. Patients confirmed as having genotype 1 HCV infection 
were assessed for suitability for treatment with ledipasvir 90mg/sofosbuvir 400mg (Harvoni®, 
Gilead) (EMC, 2016). 
Conventional care pathway 
In these pharmacies, the pharmacist opportunistically discussed with the patient the 
possibility of HCV infection and provided verbal and written information about testing and or 
treatment.  If the patient consented and had not been recently tested, a DBST was taken 
and sent to the local laboratory. In Tayside, the DBST reports Anti-HCV, Hepatitis B surface 
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antigen (HBsAg) and Anti-HIV. DBSTs reactive for anti-HCV are confirmed through 
venepuncture and PCR to determine genotype and viral load. 
The local laboratory sent back the result of the DBST to the pharmacist, with results for 
HCV, hepatitis B and HIV (NHS Tayside MCN, 2012).  The identity of each patient 
approached and the result of their DBST was recorded on a screening log.  For patients with 
a reactive DBST, a standard referral letter was sent to the treatment centre and an 
appointment letter issued, inviting the patient to attend a clinic.  For patients admitting to a 
recent HCV test, a standard referral letter was also sent to the treatment centre as described 
above.  For patients attending the appointed clinic, assessment and treatment was carried 
out as normal within the standard of care. 
Pharmacist-led pathway 
In these pharmacies the pathway was identical to the conventional pathway, except that 
patients with a reactive DBST were assessed by the pharmacist for treatment.  For 
consenting patients, the pharmacist completed a pre-treatment checklist of co-morbidities, 
medical history and concomitant medication.  The patient was invited to attend a local 
phlebotomy service and have a panel of blood tests taken including markers of liver fibrosis 
(Castera, 2012) and viral parameters (genotype and load). The pharmacist used a Fib 4 test 
result to identify patients that required further assessment and input from the hospital-based 
multi-disciplinary team (Sterling 2006).  Patients with a score of 3.25 or above were excluded 
from the study and referred to the multi-disciplinary team.  These bloods were part of 
standard care for HCV treatment and are not research specific (i.e., they were also part of 
the conventional pathway). If the pharmacist identified no contra-indications to HCV therapy, 
the patient was commenced on treatment. Prescriptions were written by a pharmacist 
independent prescriber.  In patients with potential contraindications or queries about 
suitability, the pharmacist contacted the central clinical co-ordinator for medical review. 
Unsuitable patients were referred for assessment outside the study, through the 
conventional care pathway. Patients received daily HCV treatment at the same time as their 
OST, (usually on 5 or 6 days, so a modified version of DOT).  For weekend doses (when the 
patient self-administered), the pharmacist and patient made a brief if-then action plan (an 
implementation intention) and coping plan (to overcome anticipated barriers) (Gollwitzer and 
Shearer, 2006). 
Outcomes: 
Participating pharmacies were asked to test all consenting and eligible patients from the 
cohort who attended the pharmacy.  Trial outcomes were (1.) The proportion of OST patients 
accepting the offer of testing, (2.) the proportion of patients undertaking assessment for 
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treatment, (3.) the proportion of patients completing treatment. The study endpoint was when 
all patients had completed the study care pathway or had dropped out. 
Analysis of data: 
 We have summarised study data as means (standard deviations), with t tests or chi squared 
tests used, respectively, to compare between-group baseline parameters.  The outcomes 
from the participant flows were assessed by chi squared and non-parametric significance 
testing. Since this was a feasibility study, no sample size calculation was performed. 
Data collection 
Baseline information on age, sex, concomitant medication, co-morbidities and assessment 
outcomes was collected. Subsequent data was collected on a daily administration log which 
recorded attendance and any treatment side-effects.  Participants completing treatment were 
invited for a blood test at twelve weeks to ascertain SVR.  Recruitment commenced in 
November 2015 with the study being completed in September 2016. 
Process evaluation 
A logic model was constructed to explicitly identify targets for evaluation and data collection 
and is reported elsewhere (Radley et al, 2017).  The evaluation examined the processes 
involved with effectiveness of implementation (Murray et al, 2010). 
Semi-structured interviews were conducted with (i) 6 service users and (ii) 8 professionals 
taking part in the study, with all 8 pharmacies represented.  The service users who had 
completed treatment or who had been asked to attend for assessment blood tests were 
interviewed where possible. Interviews were conducted using topic guides developed in line 
with the research aims and programme theory. All interviews were recorded as digital audio 
files and transcribed in full for thematic analysis (Richie and Spencer, 1994). Transcripts 
were inductively analysed to identify themes emergent from the interviews.  These data 
contributed to the assessment of feasibility and acceptability (including barriers and 
facilitators), that had been gained from this and previous work (Radley et al, 2016, 2017). 
Resource utilisation of conventional and pharmacist-led pathways 
The stages and inputs contained within the conventional treatment pathway were defined 
through discussion and agreement within the multi-disciplinary team.  The stages and inputs 
contained within the pharmacist-led pathway were defined by the study protocol and 
reviewed and agreed by the study team. 
Cost collection methods 
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NHS Reference costs, published micro-costing studies, and Personal Social Service 
Research Unit costs (PSSRU) (Shepherd et al, 2007), were used for the unit costs of 
managing patients while on treatment.  
Monitoring costs refer to the costs of monitoring the patient while they are treated with DAA 
therapy. Monitoring unit costs were predominantly taken from a micro costing (NHS 
Reference Costs, 2015) and were inflated to 2014/2015 costs using the Hospital and 
Community Health Services (HCHS) Pay and Prices Index (Stevenson, 2012 et al). NHS 
Reference Costs were also consulted as a possible source for this analysis. Although these 
sources were broadly aligned, more detailed costing data was available, which was essential 
for this analysis (NHS Reference costs, 2015; Curtis and Burns, 2015).  
The unit costs used to estimate the total monitoring costs and service costs for each 
pathway are displayed in Table 4. Service costs refer to the costs of services (e.g. 
pharmacist time, nurse time, consultant time) provided to the patient while they are treated 
with DAA therapy. Unit costs were predominantly taken from PSSRU Unit Costs of Health 
and Social Care 2015. Unit costs are calculated from NHS reference costs and have been 
uprated using the HCHS pay & prices inflator (Shepherd et al, 2007).  
Assessment of pathway costs 
Using the pathway map, monitoring and services costs were summed to cost both the 
conventional and Pharmacy Pathway. Service unit costs were multiplied by the staff time 
taken to complete that activity to provide the cost per activity.  
Results 
Baseline parameters: 
There was no significant difference between the age distributions of participants in the 
conventional pathway (m=38, sd = 7) and in the pharmacist-led pathway (m=37, sd = 8); t 
(504) =1.65, p=0.100 (Table 1).  Chi Square testing showed no significant differences for sex 
(p<0.4) or the hepatitis C test status parameters between the two participant groups (p<0.7). 
The testing and treatment status of both groups at baseline were compared.  Mann Whitney 
U Testing demonstrated no significant differences between the hepatitis C testing 
parameters (Ustat>UCrit ɑ=0.05). 
Recruitment and participant flow: 
Of 506 patients attending the 8 pharmacies for OST, 175 were identified as having no record 
of a previous test (35%) for HCV (Table 2) through a data linkage exercise linking OST 
prescription records with laboratory testing records.  Pharmacies randomised to the 
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conventional pathway obtained 58 DBST from 244 patients in receipt of OST (24%). Of 
these, 15 new reactive tests and 33 new negative tests were identified. The pharmacists 
also tested 2 participants who were known positives and repeated tests on 8 participants 
who had been tested in the last twelve months. 
Within the pharmacist-led pathway, 94 DBST were obtained from 262 patients in receipt of 
OST (36%).  Of these, 26 new reactive tests and 54 new negative tests were identified.  The 
pharmacists also tested 4 participants who were known positives and repeated tests on 10 
participants who had been tested in the previous twelve months.  The difference between 
these variables was significant (p<0.003).  Participants in the pharmacist-led pathway were 
more likely to take a DBST. 
Variability in uptake of testing per site was also assessed to evaluate the relationship 
between number of tests and numbers of OST patients attending each pharmacy (Table 3). 
A significant difference was identified between pharmacies in the conventional pathway 
(p<0.002). A significant difference was also identified between pharmacies in the 
pharmacist-led pathway (p<0.00002).  The uptake of testing of OST patients was therefore 
shown to vary significantly between different pharmacies participating in the trial in both 
pathways. 
Outcomes from testing and treatment: 
When a DBST was found to be reactive, participants had either to attend an appointed clinic 
in the conventional pathway or attend a local phlebotomy service in the pharmacist-led 
pathway (Table 2).  Of the participants referred through the conventional pathway, six from 
fifteen patients attended at clinic for assessment (27%). Of the participants assessed for 
treatment in the pharmacist-led pathway, twenty from twenty six patients attended for 
assessment blood tests (77%).  A Chi Square test of independence was performed to 
examine the relationship between numbers of participants proceeding through the 
assessment for treatment.  The difference between these variables was significant 
(p<0.002). Participants in the pharmacist-led pathway were more likely to proceed through 
the assessment for treatment.  Of note, a larger number of genotype 3 patients were seen in 
the pharmacist-led arm, than the conventional pathway arm (7 versus1), and these patients 
were therefore unable to proceed to treatment in this study. 
In this study, one participant completed treatment through the conventional pathway and 
three patients completed treatment through the pharmacist-led pathway.  A number of 
reasons for exclusion from treatment were responsible for patient attrition from the 
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pathways, including spontaneous clearance of HCV and identification of a genotype 3 HCV 
infection.  A flow chart of patient disposal is presented in Figure 1 
Process evaluation 
Interviews were held with participants who had either completed the pathway or who had 
tested positive but not yet attended for assessment blood tests. Examples of quotations are 
set out in Figure 2. 
How did participants feel about treatment in pharmacies? 
The transcripts of participant interviews demonstrated positive perceptions of treatment in 
pharmacies.  Interviewees clearly thought that pharmacies were a good place to receive 
care and valued the positive relationships built with pharmacy staff.  Lack of money meant 
travelling to a local hospital was a barrier to clinic attendance. Pharmacies however were 
viewed as part of the local community.  Participants were apprehensive about experiencing 
stigma and discrimination if people knew of their HCV infection. 
Participants noted that treatment with DAAs initially made them feel sick and tired, although 
this quickly faded.  On completion of the course of treatment participants expressed positive 
views about their future and described plans to move their life on. 
What feedback on implementation was received from staff? 
Interviews were held with a member of staff from each pharmacy in both pathways. Both 
pharmacists and pharmacy support staff were interviewed. Examples of quotations are found 
in Figure 2. 
Staff interviewees had clear views about what factors led to successful implementation. Staff 
considered that strong leadership and involving all the pharmacy team were necessary 
prerequisites for success. The intervention was less successful in areas where this was 
lacking.  The degree of enthusiasm for new roles and positive relationships with patients 
were also important.  Where the testing and treatment service was seen as the sole 
responsibility of the pharmacist, the pharmacies managed to complete fewer tests.  
Pharmacist availability was a limiting factor where this occurred.  Less tests were completed 
in pharmacies were the staff felt under pressure because of dispensing work load.  Where 
the service was seen as a team responsibility, the service was more successful and the 
intervention was able to cover a greater number of patients.  Positive relationships with 
patients were a key factor. Where these relationships were weaker, the acceptance of 
testing and the progress into treatment was less successful.  In pharmacies with strong 
patient relationships, the service was seen as part of the range of ways that the health of the 
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patients was improved. There were some initial anxieties expressed about potential contact 
with infected blood, but respondents said that these fears soon faded.  The patient 
assessment was felt to be straightforward and easy to accomplish. 
Staff appreciated that participants often needed time to come around to the idea of being 
tested and entering treatment.  The need for off-site phlebotomy was recognised as a 
weakness in the care pathway. 
Resource utilisation of conventional and pharmacist-led pathways 
The different levels of input and intervention in the conventional and pharmacist-led 
pathways are demonstrated in Figure 3.  The total cost of the conventional Pathway was 
estimated at £933 (£643 service cost, £290 monitoring cost), and the cost of the Pharmacy 
Pathway was estimated £238 (£143 service cost, £95 monitoring cost) (Table 4). Therefore, 
utilising solely the pathway costs, the difference in the cost per patient was £695 (£499 
service cost, £195 monitoring cost).  The costs associated with the pharmacy setting are 
around one quarter of the cost of treating a patient in a conventional setting (assuming the 
same cost of DAA treatment). In terms of staff capacity, the pharmacy pathway model uses 
four hours less service resources than the conventional pathway (6.66 hours with 
conventional pathway versus 2.66 hours with pharmacy pathway). 
Discussion 
Main study findings 
This feasibility study provides evidence that community pharmacies can successfully provide 
DBST to patients attending for OST and that progression to treatment is feasible.  More 
participants accepted a DBST in a pharmacist-led pathway than in the conventional 
pathway, where there was no requirement to attend a hospital clinic for treatment.  
Interviews with participants identified a number of explanatory factors for this.  This study 
found that more participants undertook assessment for treatment in the pharmacist led 
pathway, where the care pathway was delivered entirely in the pharmacy.  Both patient and 
staff experiences and views demonstrated how the pharmacist-led pathway overcame some 
of the barriers that prevent people prescribed OST accessing testing and treatment. 
Strengths and weaknesses of the study 
The criteria set out for evaluating the success of the feasibility trial included whether people 
who receive OST for pharmacies could be recruited to the study; whether pharmacies could 
successfully complete all elements of the testing and treatment pathway; which elements of 
the pathway work well and which elements are less successful; to make an estimate of the 
12 
 
effect size in terms of how many participants complete each stage of the pathway (Arain 
2010).  The study has provided evidence that these criteria can be met: OST patients can be 
recruited and pharmacies can guide patients through all stages of the pharmacist-led 
pathway. 
The need to attend for off-site phlebotomy led to some loss of potential patients in the 
pharmacist-led pathway and this weakness should be addressed in the design of the final 
pathway for full trial, with perhaps the inclusion of peripatetic phlebotomy services visiting 
pharmacies. This study demonstrated that three participants could access treatment in the 
pharmacist led pathway compared to one participant in the conventional pathway.  However, 
a series of further aspects also provide encouragement that a significant effect size is 
present, including the reduced losses at clinic attendance stage in the pharmacist-led arm.  
Notably, demonstration of a larger effect size in the pharmacist-led arm was impaired 
because of a larger proportion of patients spontaneously clearing infection and a great 
number of genotype 3 patients being identified in this arm, which at the time of the study 
could not be treated with interferon free regimens. 
Some variation in uptake was observed between pharmacies in both pathways.  Additional 
factors may explain this variation, such as the degree of enthusiasm of the pharmacy staff 
for new roles, the relative burden of dispensing workload in the pharmacy and the leadership 
shown by the pharmacist. This variance may be addressed through growing acceptance of 
this service as part of what a pharmacy should offer. 
A further limitation is the access of pharmacies to electronic laboratory results services.  
Although, these are now being implemented into pharmacies in some areas, this resource is 
not yet widely available.  The consequence of this, as identified in this study, was that some 
patients received duplicate blood tests. Additional variables such as length of time of OST 
and the dispersal of co-morbidities and BBV co-infection may also act as confounders.  The 
use of pharmacies as study sites precluded assessment of medical notes to assess these 
factors systematically, but the DBST taken from clients assessed Hepatitis B and HIV co-
infection, as well as HCV. The exclusion criteria for the study required that such patients 
were directly referred to the standard care pathway. A further large scale study is now being 
implemented to fully assess the potential of this pathway.  
Interpretation of findings 
Previous pilot work from this programme has explored the context for delivery and the 
mechanisms that may lie behind the outcomes observed (Radley, 2017).  Contextual factors 
have previously been identified by other authors, including: expectations and experiences of 
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stigma and discrimination; fears about confidentiality; the limited horizons of people receiving 
OST and the poverty they experience (Harris et al 2013, Wade et al 2016).  Identified 
mechanisms that may influence uptake included the presence of established relationships 
with pharmacy staff; a pre-existing reason for attending the pharmacy for OST and the 
proximity of the pharmacy within the local community.  The work undertaken in this study, 
has confirmed that the local nature of the pharmacy and the pre-existing reasons for 
attendance are key mechanisms in recruitment for testing and that good quality relationships 
between pharmacy staff and participants, supports recruitment (Edlin et al 2005).  The 
barriers to completion of either of the care pathways were also confirmed: that participant 
may be anxious about what the results might mean for them, or mistrustful of the way they 
might be treated.  Although the pharmacies provided a familiar environment within their local 
community, hospitals represented an unfamiliar setting.  The health literacy required to 
navigate the journey from the participant’s normal setting to attend multiple hospital-based 
appointments was a significant barrier (Arora et al 2011). For the pharmacist-led arm of the 
study, even the attendance at an external venue for a single phlebotomy appointment was a 
significant barrier, leading to patient loss from the pathway. 
Treatment pathways that increase access and uptake of treatment of DAAs are required.  
Uptake of testing and treatment is currently low (Weissing, et al, 2014) and authors across 
the world have identified many common barriers that must be overcome by potential patients 
to treat the HCV infection (Wade et al 2016, Konerman and Lok, 2016)).  There are identified 
deficiencies in the amount of screening and diagnosis undertaken for at-risk populations, as 
well as improvements required in access to treatment initiation and clinical monitoring 
(Artenie et al, 2015): The infrastructure to deliver sufficient treatment to enable eradication is 
not generally available or of sufficient scale (Leask and Dillon, 2016). People who inject 
drugs may find it difficult to consistently attend the medical clinics that are the mainstay of 
standard of care (Papatheodoridis et al, 2016).  Delaying treatment because of funding 
problems risks patients being lost to follow-up (Fox and McCombe, 2016). 
Creating the complex interventions necessary to eliminate HCV requires that well-designed 
cross-disciplinary programmes are put in place (Suther and Harries, 2016) using a variety of 
strategies to increase screening, testing and diagnosis (Brouard et al, 2015).  The delivery of 
HCV testing and treatment through community-based care pathways has been shown to be 
feasible (Coats and Dillon, 2015). 
There have been a number of different routes chosen to provide primary care-based 
treatment pathways.  A targeted general practice-based screening intervention has been 
recommended, since low diagnostic yields limited the effectiveness of non-targeted 
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approaches (Anderson et al, 2009).  Current work aims to produce a scalable general 
practice model (Roberts et al, 2016).  Community-based, nurse-led care for HCV has shown 
been shown to be effective (Wade et al, 2015). The change away from interferon-based 
regimes should improve the proportion of people who are willing to undertake treatment 
(Lewis et al, 2016). 
As well as the benefits that arise from harnessing the established OST care system already 
implemented in the pharmacy, such as improved regime adherence, there are further 
benefits gained through developing a new pathway designed to take advantage of DBST 
and the reduced burden of DAA treatment. The lower cost of primary care premises 
compared to hospital clinics as well as the simplified testing and monitoring requirements, is 
responsible for the lower estimated cost of the pharmacist-led pathway. These lower costs 
are likely to prove favourable even if current hospital-based standard of care pathways are 
also simplified and made more efficient. Although the conventional care pathway reported in 
this study required twelve attendances to complete treatment, other authors have reported 
pathways with up to eighteen stages (Arora 2011)  With current pathways, the use of DAAs 
is cost-effective at all stages of liver disease (Leidner et al, 2015, Liu et al, 2012).  With 
primary care based care pathways capable of recruiting greater numbers of people with HCV 
infection, cost-effectiveness of these medicines may increase further (Bennett et al, 2016).  
A coordinated programme delivered through a managed care network has increased the 
numbers of people accessing treatment and shortened the time for people with HCV 
infection to achieve an SVR (Tait et al, 2016).  A multi-disciplinary approach to care has 
been demonstrated to improve care. 
Conclusions 
This feasibility study provides further evidence that service users prescribed OST can 
access testing and treatment through a pharmacy.  Use of a pharmacist-led pathway may 
remove some of the barriers that prevent OST patients accessing testing and treatment 
through conventional pathways. 
A number of the identified barriers to the uptake of testing in this study were overcome 
through the local availability of the pharmacies and positive relationships with pharmacy 
staff.  The use of community pharmacy delivered care has the potential to contribute to 
elimination of HCV in the United Kingdom.  Further work to evaluate the outcomes 
associated with this service configuration is now on-going (NHS Research Authority, 2016). 
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Table 1: Baseline characteristics of trial population by group allocation 
Characteristic Conventional pathway (%) Pharmacist-led 
Pathway 
 
    
Participants (n) 244 262  
    
Male 165 (68) 167 (64)  
Female 79 (32) 95 (36) p=0.358 
Age (years) 
   
20-24 3 (1) 7 (3)  
25-29 22 (9) 40 (15)  
30-34 65 (27) 64 (24)  
35-39 56 (23) 55(21)  
40-44 44 (18) 55(21)  
45-49 36 (15) 26(10)  
50-54 14 (6) 8(3)  
55-59 4 (2) 4(2)  
60-64 0  2(1)  
65-69 0 1 p=0.100 
Hepatitis C Status   
 
Continued Follow-Up in 
Treatment 34 (14) 32 (12) 
 
Previous SVR Completed 
Treatment 20 (8) 21 (8) 
 
Last Test Negative 89 (36) 90 (34)  
No Record of Previous 
Test 80 (33) 95 (36) 
 
Referral, Did Not Attend 4 (2) 10 (4)  
Attended, Did Not 
Complete 14 (6) 14 (5) 
p=0.622 
Positive Test, No Referral 3 (1) 0 - 
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Table 2: Participant Flow and outcomes 
Population 
 
 Pool of 2,200 patients in Tayside receiving OST 
Cohort 
 
 506 patients receiving OST in 8 participating pharmacies 
   
 Conventional Pathway Pharmacist‐Led Pathway 
 244 OST patients 262 OST patients 
 
    Tested 
 p=0.00299 
 58 DBST taken 94 DBST taken 
 
Assessment 
  p=0.00165 
   
   
   
   
   
   
   
   
 
Follow-Up 
   
   
   
   
   
   
   
  
   
  
Treatment 
  
1 patient treated 
 
3 patients treated 
 1 completed treatment at 12 weeks 3 completed treatment at 12 weeks 
 
15 new reactive tests 
33 new negative tests 
2 known HCV retested 
      
26 new reactive tests 
54 new negative tests 
4 known HCV retested 
      
11 DNA at clinic post ‐referral 
1 genotype 3 
1 Spontaneous clearance 
0 Prison 
1 Deceased 
6 No assessment blood test 
7 genotype 3 
9 Spontaneous clearance 
1 Prison 
0 Deceased 
22 
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Table 3 Patient Outcomes – Uptake of testing and treatment by pharmacy site 
 
Site No. Patients 
No record of 
previous test 
DBST 
(%) 
Known 
positives 
Repeat 
test 
New 
positives 
New 
negatives 
1 68 25 11 (16) 0 0 0 11 
2 76 26 21(28) 2 2 7 10 
3. 62 19 9(15) 0 3 2 4 
4. 38 10 17(45) 0 3 6 8 
Totals 244 80 58(24) 2 8 15 33 
        5 84 39 43 (51) 1 1 10 31 
6 51 19 7(14) 0 0 2 5 
7 86 21 20(23) 3 6 5 6 
8 41 16 24(59) 0 3 9 12 
Totals 262 95 94(36) 4 10 26 54 
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Figure 1:  Percent Attrition of Patients with Reactive Tests for Conventional and Pharmacist-Led Pathways  
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Figure 2: Examples of quotations from service users and staff participants 
Service Users  
How did Hepatitis C affect your life? 
“I already knew I had Hepatitis C, I got diagnosed with it more than 10 years ago. I had 
always been waiting for the time ... my life just never seemed to get to a point where it was 
stable enough to do it” Participant 1, male 
“A couple of years ago I said to one of my pals there wus somethin’ wrang wi’ us, I was just 
tired, no strength to go any place” Participant 2, female 
What was your experience of treatment in the pharmacy? 
“I recognise that this is a big plus, being able to get a tablet every day at the chemist is so 
ease, so convenient”. Participant 4, male 
“When you got to the hospital sometimes you feel like you are being treated differently and I 
just found that in here(in the pharmacy) it was a more warmer environment and friendly” 
Participant 6 male 
Has completing treatment made any differences to you? 
“But I honestly feel different; I feel like my old self ken, I feel better” Participant 1, male 
“Going forward now it more just that, eh I want to go back to college and get into youth work 
if I can.  I have a prospectus as home, so my future .. what I see is me hopefully doing 
something along lines”. Participant 2, Female 
 
Staff 
How did you feel about taking part in the study? 
“I was quite excited about it, quite looking forward to doing it, it was something quite different 
for pharmacies to do, we would get more involved with the methadone patients, so I was 
very interested and keen for it”. Staff Member 7, Female 
How did you manage the participants and help them to complete the pathway? 
“you build up your conversations and your style of conversations, the more you gain in 
confidence, the better the client feels and they also like to understand that we are learning 
and developing with them, they like to feel part of something too”. Staff member 3, Female 
“We did try quite a few times to get him to go but he kept said he would be going, in fact I 
think once he said he had gone but he wasn’t able to get tested, but I don’t know if that’s 
true or not”.  Staff Member 5, Male 
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Figure 3: Conventional and Pharmacist-Led Pathways 
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Table 4: Monitoring costs and service costs  
 
Conventional Pathway Costing Results  
Stage Reason Activity  (Estimated Staff Time hrs) 
Cost 
(per activity) 
1 Dried Blood Spot Test Specialist Nurse (0.33) £41 Dried Blood Spot Test £40 
2 Outpatient appointment Specialist Nurse (0.66) £83 Liver Panel  £5 
3 Outpatient Appointment Ultrasonographer (0.5) £20 Fibroscan £55 
4 Appointment Medical Clinic Consultant (0.5) £69 Liver Panel  £5 
5 Radiology Appointment Ultrasonographer (0.5) £20 Ultrasound Liver  £63 
6 Medical Clinic Appointment Consultant / Registrar (0.33) £24 
7 Outpatient Clinic Appointment 
Specialist Nurse (0.5) £63 
Liver Panel  £5 
8 Prescription Pharmacist Prescriber (8a) (0.5) £36 
9 Outpatient Review Specialist Nurse (0.33) £41 Liver Panel  £5 
10 Outpatient Review Specialist Nurse(0.33) £41 Liver Panel  £5 
11 Outpatient Review Specialist Nurse (0.33) £41 Liver Panel  £5 
12 Outpatient Review Specialist Nurse (0.33) £41 Liver Panel  £5 
13 Outpatient Review Specialist Nurse (0.33) £41 SVR £50 
14 Outpatient Review Specialist Nurse (0.33) £41 SVR £5- 
15 Discharge Specialist Nurse (0.33) £41 
Total Pathway Cost  £933 
     Service Cost  £643 
     Testing Cost  £290 
 
Pharmacy Pathway Costing Results  
Stage Reason Activity  (Estimated Staff Time hrs) 
Cost  
(per activity)  
1 Pharmacy Attendance for Methadone Pharmacist (0.33) £17 
2 Dried Blood Spot Test in Pharmacy 
Pharmacy Assistant (0.33) £3 
Dried Blood Spot Test £40 
3 Assessment Blood Tests 
Specialist Nurse (0.33) £25 
Liver Panel  £5 
4 Patient Assessment in Pharmacy Pharmacist (0.5) £25 
5 Prescription Pharmacist Prescriber (band 8a) (0.5) £25 
6 Outpatient Review (SVR test) 
Specialist Nurse (0.33) £25 
SVR £50 
7 Discharge from Service Specialist Nurse (0.33) £25 
Total Pathway Cost £238 
Staff Cost  £143 
Testing Cost £95 
 
